Silexion Therapeutics to Acquire 03 Life Sciences
Ticker: SLXNW · Form: 8-K · Filed: Sep 25, 2025 · CIK: 2022416
Sentiment: neutral
Topics: acquisition, biotechnology, merger
Related Tickers: SLXN
TL;DR
Silexion is buying 03 Life Sciences, deal expected to close Q4 2025.
AI Summary
Silexion Therapeutics Corp. announced on September 23, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of 03 Life Sciences. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition could significantly expand Silexion's pipeline and market presence in the biotechnology sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and potential failure to achieve expected synergies.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- 03 Life Sciences (company) — Target company for acquisition
- September 23, 2025 (date) — Date of the definitive agreement
- fourth quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on the "Other Events" of Silexion Therapeutics Corp., specifically announcing a definitive agreement to acquire 03 Life Sciences.
When did Silexion Therapeutics Corp. change its former company name?
Silexion Therapeutics Corp. was formerly known as Biomotion Sciences, and the date of the name change was May 6, 2024.
What is the expected closing timeframe for the acquisition of 03 Life Sciences?
The acquisition of 03 Life Sciences is expected to close in the fourth quarter of 2025.
Where is Silexion Therapeutics Corp. headquartered?
Silexion Therapeutics Corp.'s principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.
What is the SIC code for Silexion Therapeutics Corp?
The Standard Industrial Classification (SIC) code for Silexion Therapeutics Corp. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 926 words · 4 min read · ~3 pages · Grade level 14.5 · Accepted 2025-09-25 08:00:01
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
- $2.5 million — intain shareholders' equity of at least $2.5 million (the " Equity Requirement "), and Nasda
- $1.00 — any, to maintain a minimum bid price of $1.00 per share (the " Minimum Bid Price Requ
- $10.3 million — pro forma basis as of July 31, 2025 by $10.3 million to approximately $9.41 million as of Se
- $9.41 million — 2025 by $10.3 million to approximately $9.41 million as of September 15, 2025. Also as prev
Filing Documents
- zk2533805.htm (8-K) — 50KB
- 0001178913-25-003374.txt ( ) — 221KB
- slxn-20250925.xsd (EX-101.SCH) — 5KB
- slxn-20250925_def.xml (EX-101.DEF) — 18KB
- slxn-20250925_lab.xml (EX-101.LAB) — 27KB
- slxn-20250925_pre.xml (EX-101.PRE) — 20KB
- zk2533805_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. Nasdaq Confirmation of Restoration of Compliance with Shareholders' Equity and Minimum Bid Price Listing Requirements On September 23, 2025, Silexion Therapeutics Corp. (the " Company ") received a letter from The Nasdaq Stock Market LLC (" Nasdaq ") (the " Compliance Letter ") confirming that the Company has demonstrated compliance with both Nasdaq Listing Rule 5550(b)(1), which requires an issuer, such as the Company, listed on the Nasdaq Capital Market to maintain shareholders' equity of at least $2.5 million (the " Equity Requirement "), and Nasdaq Listing Rule 5550(a)(2), which requires a listed issuer, such as the Company, to maintain a minimum bid price of $1.00 per share (the " Minimum Bid Price Requirement "). As previously reported, following a hearing with the Nasdaq Hearings Panel (the " Pane l") on June 26, 2025, the Company received a favorable decision letter from the Panel on July 7, 2025, granting the Company's request to continue its listing on Nasdaq, subject to the Company demonstrating compliance with the Equity Requirement by September 19, 2025. As affirmed by the Company in its Current Report on Form 8-K filed on September 15, 2025, the Company completed a series of financing transactions, which collectively increased the Company's shareholders' equity on a pro forma basis as of July 31, 2025 by $10.3 million to approximately $9.41 million as of September 15, 2025. Also as previously reported, on July 18, 2025, the Company received a letter from the Listing Qualifications Department (the " Staff ") of Nasdaq notifying the Company that, for the 30 consecutive business days preceding the letter, the closing bid price of the Company's ordinary shares was below the minimum $1.00 per share required for compliance with the Minimum Bid Price Requirement. The Staff indicated in the letter that the Panel would consider the bid price deficiency in its decision as to whether to enable the Company to remain listed on the Nasda